Mon, December 6, 2021
Sat, December 4, 2021
Fri, December 3, 2021
Thu, December 2, 2021
Wed, December 1, 2021
Tue, November 30, 2021
Mon, November 29, 2021
Fri, November 26, 2021
Wed, November 24, 2021
Tue, November 23, 2021

Debjit Chattopadhyay Maintained (VRTX) at Strong Buy with Increased Target to $286 on, Dec 1st, 2021


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-286-on-dec-1st-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Debjit Chattopadhyay of Guggenheim, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $250 to $286 on, Dec 1st, 2021.

Debjit has made no other calls on VRTX in the last 4 months.



There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 3 agree with Debjit's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Do Kim of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $218 on, Friday, November 19th, 2021
  • Evan Seigerman of "BMO Capital" Initiated at Hold and Held Target at $202 on, Friday, November 19th, 2021
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $213 on, Thursday, September 9th, 2021


These are the ratings of the 4 analyists that currently disagree with Debjit


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $250 on, Wednesday, November 3rd, 2021
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Tuesday, November 2nd, 2021
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Tuesday, October 19th, 2021
  • Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell and Held Target at $202 on, Tuesday, September 7th, 2021

Publication Contributing Sources